Speakers are listed below in alphabetical order by family name.
Gordon R. Bernard
Lecture Title: Personalized Medicine and the Translational Research Space at Vanderbilt University
Personalized Medicine in the Translational Space at Vanderbilt University
Gordon R. Bernard, Vanderbilt Institute for Clinical and Translational Research (IVCTR), Vanderbilt University, Nashville, TN 37232 (email: email@example.com )
The Vanderbilt Institute for Clinical and Translational Research was established to identify, facilitate and create disease-agnostic infrastructure, resources and training, across the entire clinical and translational spectrum. VICTR is designed to systematically remove impediments to translation, create research enabling infrastructure, and establish training programs for the next generation of translational investigators. Support for this institute is jointly shared by both the NIH and Vanderbilt. Major adjustments in the administrative structure of Vanderbilt Medical Center were made in order to facilitate accomplishment of the above goals. VICTR supports a robust pilot funding program, studios for individual investigator support, a porfolio of software tools needed for clinical research, a 14-bed in inpatient as well as an outpatient clinical research unit, the PREDICT and BioVU programs. The PREDICT program is designed to provide just-in-time genotype information to guide clinical care and the BioVU program is one of the largest DNA banks in the world. The DNA samples are linked to complete medical records and both are deidentified to facilitate collection and maintenance of the samples. BioVU has been used to conduct nearly $100M in research on questions related to genomic medicine.
This work was supported by the National Institutes of Health, CTSA award Nos. UL1TR000445, KL2TR000446, and TL1TR000447 from the National Center for Advancing Translational Sciences and from Vanderbilt University.
Gordon R. Bernard, MD, is Associate ViceChancellor for Research, Director of the Vanderbilt Institute for Clinical and Translational Research, and P.I. of Vanderbilt’s Clinical and Translational Science Award (CTSA), Dr. Bernard oversees a multifaceted translational research center in addition to directing his own research programs. Dr. Bernard’s research has primarily focused on improving the care and outcomes of critically ill patients with sepsis and the acute respiratory distress syndrome (ARDS). Because of his expertise in this area, Dr. Bernard has been called upon to serve in an advisory capacity by the National Heart Lung and Blood Institute of the National Institutes of Health and chairs the steering committee for the NHLBI’s ARDS Clinical Trials Network. Additionally, Dr. Bernard provides his expertise to physician scientists internationally via invited lectures and through his role as advisor to global companies and organizations involved in health care, which includes advisory board service to the nonprofit International Sepsis Forum. Dr. Bernard is also currently the director for Coordinating Center for the NIH National Consortium of CTSAs and is a member of the American Association of Physicians and has written or co-authored more than 250 articles, book chapters and editorials.
Lecture Title: Connecting Precision Medicine to Precision Wellness towards a systems understanding of health and disease
This talk will focus on Mount Sinai’s efforts at the nexus of Big Data, Multiscale biology, and precision medicine. Dr. Dudley will discuss how Mount Sinai is applying the latest technologies from digital health, data science, and molecular profiling to organize, integrate, and learn from the digital universe of information towards better understanding of patient populations, disease mechanisms, and drug response.
Dr. Dudley is currently Assistant Professor of Genetics and Genomic Sciences and Director of Biomedical Informatics at Mount Sinai School of Medicine. Prior to Mount Sinai, he held positions as Co-founder and Director of Informatics at NuMedii, Inc. and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University School of Medicine, where he participated in leading research to incorporate genome sequencing into clinical practice (published in The Lancet, Cell, and PLoS Genetics). Dr. Dudley’s current research is focused towards solving key problems in genomics and precision medicine through the development and application of translational and biomedical informatics methodologies. His lab publishes in the areas of bioinformatics, genomic medicine, personal and clinical genomics, as well as drug and biomarker discovery. His recent work with co-authors describing a novel systems based approach for computational drug repositioning (published in Science Translational Medicine) was featured in the print edition of the Wall Street Journal, and earned designation as the NHGRI Director’s Genome Advance of the Month. He is co-author of the book Exploring Personal Genomics from Oxford University Press. He received a BS in Microbiology from Arizona State University and an MS and PhD in Biomedical Informatics from Stanford University School of Medicine.
Lecture Title: The Path to a Billion People: Genetics and Genomics on course for Mainstream Medical Practice
Driving down the price of DNA sequencing will increase the clinical and personal utility of genetic information, enabling the generation, analysis and storage of more comprehensive genetic information than ever before. By aggregating large numbers of currently available genetic tests into a single service, we can achieve great economies of scale that allow us to not only provide primary single gene or multi-gene tests, but also to generate and store additional genetic information on behalf of the patient for future use. In addition, as more individuals gain access to their genetic information, we believe that sharing that information will provide an economic opportunity for patients and us to participate in advancing the understanding and treatment of disease and revolutionizing mainstream medicine.
Genes are a fundamental particle of modern medicine, and genetic testing has the potential to affect billions of people. Every individual has a unique genome and having comprehensive knowledge of this genetic makeup will be foundational to the future practice of medicine.
Sean George is co-founder, president and chief operating officers of Invitae, a genetic information company dedicated to bringing genomic information to mainstream medical care. Prior to co-founding Invitae, he served as the chief operating officer at Navigenics, an early leader in personalized medicine. He has also served as senior vice president of marketing at Affymetrix, senior vice president of life science business at Affymetrix, and vice president of labeling and detection business at Invitrogen. He has worked at McKinsey & Company and Molecular Probes as well. Dr George holds a Bachelor of Science from UCLA with a major in molecular genetics, a Master of Science in molecular biology from University of California, Santa Barbara and a doctorate in molecular genetics from University of California, Santa Cruz.
Sir Malcolm Grant
Lecture Title: Developing personalised medicine in the NHS and the 100,000 genomes project
Developing personalised medicine in the NHS and the 100,000 genomes project
Professor Sir Malcolm Grant1
1Chairman, NHS England and board director, Genomics England Ltd
The UK Government committed to the100,000 genomes project at the end of 2012, and work is now well advanced. It is at the cutting edge of clinical science and technology, but from the perspective of NHS England, this was not to be simply a research project, but a project of clinical transformation through personalised medicine. It has involved a close partnership with Genomics England Ltd (GEL), a wholly government owned company. Over the past 2 years the cost of whole genome sequencing has continued to fall dramatically, and improvements continue to be made in accuracy. We are confident that the technology can deliver, and GEL have procured Illumina to undertake the first substantial phase of the work, at a facility being constructed outside Cambridge in the UK adjacent to the Sanger Centre and with the support of the Wellcome Trust.
The clinical challenge is more complex. A patient consent form and procedure has now been agreed. We have appointed through competition a group of 11 Genomic Medicine Centres of clinical and academic staff, regionally distributed across England. Their initial role is to acquire clinical samples of the necessary quality and match them with phenotypic data, in relation to the three initial areas of inquiry, rare inherited diseases, infection and cancers (trials continue in order to improve the quality of both paraffin embedded and fresh frozen samples) .We are setting up arrangements not only for sequencing, alignment and variant calling, but also for clinical interpretation, reporting and a cohort analysis for all 100,000 genomes. We anticipate that this will involve several non-exclusive partnerships to ensure we source the best expertise in the world; in addition, there has been exceptionally strong interest across the clinical academic community in participating in a new GE Clinical Interpretation Partnership with several domains for both cancer and rare diseases.
Professor Sir Malcolm Grant is the founding chairman of NHS England, the independent body established in 2012 to manage the NHS budget by procuring high quality healthcare for the population. NHS England is currently leading a program of transformational reform of healthcare provision. He is also a board director of Genomics England Ltd . He was formerly for 10 years President and Provost of University College London (UCL), and before then pro-Vice Chancellor of Cambridge University. He is a barrister by profession, and a New Zealander by birth. Later this year he takes up the honorary role of Chancellor of the University of York.
Lecture Title: A Decade of Direct Access Genetics: What Have We Learned?
A Decade of Direct Access Genetics: What Have We Learned?
Dr. Jill Hagenkord, 23andme, Mountain View, CA
Over the past ten years, direct access genetics has played a critical role in personalized medicine and accelerating research. The journey to make genetic information accessible and affordable for all has not been without challenges. Despite the hurdles, we are making progress towards a healthier, more informed consumer who wants their data used for greater good. Dr. Jill Hagenkord will discuss the importance of DTC and big data to further medical advancements and ultimately, improve health care.
Dr. Jill Hagenkord joined the company in 2014 and serves as chief medical officer for 23andMe where she is responsible for all medical affairs activities serving as the company liaison to physician, medical, genetics and research industry groups. Jill also oversees laboratory, shipping and fulfillment operations for the company.
Previously, Jill served as senior vice president of medical strategy for InVitae Corporation, a genetics information company, where her role included serving as medical director, contributing to corporate strategy, acting as commercial liaison, and leading the company’s physician education programs.
Jill is a board-certified molecular genetic pathologist. Prior to joining Invitae, she served as chief medical officer and senior vice president at Complete Genomics, Inc. Her other prior experiences include founder and chief medical officer for iKaryos Diagnostics, associate professor of pathology at Creighton University School of Medicine, director of molecular pathology and clinical genomics at Creighton Medical Laboratories, and pathologist at Deltagen, Inc. Jill received her M.D. from Stanford University School of Medicine in 1999, did her residency training in pathology at the University of California at San Francisco and the University of Iowa, and completed fellowships in pathology/oncology informatics and molecular genetic pathology at the University of Pittsburgh Medical Center.
Lecture Title: Systems Medicine and Proactive P4 Medicine: Catalyzing a Revolution in Healthcare through a Longitudinal, Digital-Age Study of 100,000 Well Individuals
Systems Medicine and Proactive P4 Medicine: Catalyzing a Revolution in Healthcare through a Longitudinal, Digital-Age Study of 100,000 Well Individuals
Lee Hood, Institute of Systems Biology, Seattle, WA
Systems medicine is the application of systems-biology approaches to disease. I will focus on several new opportunities that emerge from systems medicine and illustrate how these transform how we approach disease and healthcare. These include dynamical studies of disease-perturbed biological networks, the complete genome sequence analyses of families to identify disease genes, and a systems-approach to blood diagnostics. Systems medicine has reached a tipping point and is already beginning to transform the practice of medicine. Three converging opportunities—systems medicine, big data (and its analytics) and patient-activated social networks—are leading to a proactive medicine that is predictive, personalized, preventive and participatory (P4). I will contrast P4 medicine with contemporary evidence-based medicine and discuss its societal implications for healthcare. I will discuss how we plan to introduce P4 medicine into the current healthcare system with a P4 pilot program—a longitudinal, digital-age study on 100,000 well patients. We are already 10 months into a study of 107 well individual and the preliminary results from these studies are striking. These advances will have profound implications for healthcare and society.
Leroy Hood, M.D., Ph.D., firstname.lastname@example.org
Dr. Hood’s research has focused on the study of molecular immunology, biotechnology, genomics, systems biology and systems medicine. His professional career began at Caltech
where he and his colleagues pioneered four instruments—the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer—which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s.
His studies on antibody diversity transformed our understanding of the mechanisms for producing antibody diversity.
In 1992, Dr. Hood moved to the University of Washington as founder and Chairman of the first cross-disciplinary department in biology–the Department of Molecular Biotechnology. In 2000, he co-founded the first Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine. It was during this time that he began his systems-driven studies on neurodegeneration and cancer. Dr. Hood was elected to the Inventors Hall of Fame for the automated DNA sequencer. In addition, his lifelong contributions to biotechnology have earned him the 2006 Heinz Award in Technology, the Economy and Employment for his extraordinary breakthroughs in biomedical science at the genetic level; the prestigious 2004 Biotechnology Heritage Award; the esteemed 2003 Association for Molecular Pathology (AMP) Award for Excellence in Molecular Diagnostics; and the 2003 Lemelson–MIT Prize for Innovation and Invention. He was also awarded the 2002 Kyoto Prize in Advanced Technology, and the 1987 Lasker Prize for his studies on the mechanism of immune diversity. In 2011 he received the NAE’s Russ Prize for developing the automated DNA sequencer that revolutionized genomics and medicine. In 2013 he received the National Medal of ‘Science from President Obama.
He has published more than 750 peer-reviewed papers, received 36 patents, and has co-
authored textbooks in biochemistry, immunology, molecular biology, and genetics and is now finishing an elementary text book on systems biology. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. He is one of 15 (of more than 6,000 members) scientists elected to all three academies (NAS, NAE and IOM). Dr. Hood has also played a role in founding 15 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin, Rosetta, and the newly formed diagnostic company, Integrated Diagnostics. He is currently pioneering systems medicine and the systems approach to disease.
Lecture Title: Designing and building a 21st century consumer health service.
Designing and building a 21st century consumer health service.
James R. Kean, National Pro Grid League, 16420 SE McGillivray Blvd, Ste 103-735, Vancouver, WA 98683 (email: email@example.com)
Since the first internet browser gained popularity in the mid 1990s, the promise of digital service delivery has been to provide more access and information to consumers while improving quality of service. At the same time for healthcare professionals, the redesign of such technologies, user engagement front ends and service delivery represents the potential to free up valuable highly trained professionals to do what they love and were trained for. While twenty years has seen the implementation of some such strategies, for the most part, most consumer healthcare services remain in the 20th century. However, 20 years of thinking and investment in these areas has begun to see the rise of innovative service models designed around consumer engagement and customer service measures seen in other consumer driven industries. This should accelerate over the next decade.
Spanning two decades, Jim’s career has focused on the design of highly recognized consumer facing digital products and service delivery in the health, wellness and fitness spaces.
Presently, he is CEO of the National Pro Grid League (NPGL). Designed and released in 2014, GRID is the world’s first professional spectator sport with two co-ed teams racing head-to-head in a two-hour match. It incorporates speed, skill and strategy in a test of endurance through a variety of weightlifting and body-weight elements. Featured on NBC, the user experience represents a leading edge combination of TV, digital, social, and in venue elements for fan engagement that has been recognized for its innovative design.
In 2010, Jim was Founder and CEO of WellnessFx™ a San Francisco based company that is making it easy and affordable for consumers to manage key areas of their healthcare lives. WellnessFX provides inexpensive, profile driven access to targeted health content, diagnostic and telehealth services, and HIPAA secure storage. From inception, the company has received almost yearly recognition on a variety of fronts for its innovative consumer service. Most recently, in 2014 it was recognized as one of the 10 Ten Health and Fitness applications in Fast Company’s annual awards. In December 2013 the company merged with Health Elements/Thorne Research in a private transaction. Jim has continued forward with the company as a board member.
In 1995, Jim founded Sapient Health Network (SHN) which became the Consumer facing business of WebMD. As President of SHN, Jim pioneered the concept of online consumer health communities, building some of the largest and most loyal groups on the Web today. The company’s service was named one of the “Seven Best Websites of 1998” by Business Week. In 1999, SHN merged with WebMD and today over 23 million consumers per month visit WebMD for health advice.
He graduated with a BA in Economics from Lewis & Clark College in Portland, OR and his MBA from Tuck School at Dartmouth.
Title: The BC Cancer Agency’s Personalized Onco-Genomics Project
The BC Cancer Agency Personalized OncoGenomics (POG) Project
Marco A. Marra, Janessa Laskin and the POG Project Team
The application of “personalized” or “precision” medicine to oncology is a compelling concept based on the success of targeted agents in niche populations who express a specific drug target. To help stratify patients to therapies, single gene or multiple gene (“panel”) tests are now done routinely at the BC Cancer Agency (BCCA) and around the world. In addition, at the BCCA ,panels are being uniquely complemented by a large scale translational genomics effort to assess the feasibility of whole genome analysis to inform treatment planning. We were among the first in the world to report in 2010 the successful use of whole genome analysis to inform treatment planning for a rare cancer. This early experience, along with significant improvements in the cost and throughput of whole genome analysis, led to the launch of a POG pilot project in 2012. The aim of the pilot project was to assess the general feasibility of whole genome analysis in the context of a Canadian tertiary care cancer centre, including the uptake of whole genome technology by medical professionals. The pilot project enrolled 100 cases into study and is now complete. Lessons learned will be presented as will our planned next steps in our effort to expand the POG project to a 5,000 case cohort.
Dr. Marra is the UBC Canada Research Chair in Genome Science, and a member of the Order of British Columbia. He is a recipient of a 2013 UBC Killam Research Prize, a 2012 UBC Faculty of Medicine Distinguished Achievement Award, and the Medal of Merit Award from the International Association of Lions Club. He was elected to the Canadian Academy of Health Sciences in 2009; received the Frontiers in Research Award from the BC Innovation Council in 2008; and was appointed a Fellow of the Royal Society of Canada in 2007. He was a recipient of a Genome BC Award for Scientific Excellence, a MSFHR Career Investigator Senior Scholar Award, and a Simon Fraser University President’s 40th Anniversary Award. In 2004, he received a Terry Fox Young Investigator Award and BC Biotech’s Innovation and Achievement Award (together with the entire GSC staff) for sequencing the SARS coronavirus genome.
Dr. Marra’s contributions to genome science led to an honorary Doctor of Science degree from Simon Fraser University in 2004, and an honorary Doctor of Laws degree from the University of Calgary in 2005.
Deborah M. Money, MD, FRCSC
Lecture Title: Personalized Medicine from a women’s health perspective.
The Canadian Microbiome Initiative has funded teams across Canada to facilitate the study of the human microbiome in multiple body niches. The Vogue group, led by Dr. Deborah Money was funded by CIHR and Genome BC to study the vaginal microbiome. This study group has brought together investigators from UBC, University of Saskatchewan, the NRC Plant Biotechnology Institute, the University of Western Ontario, Guelph University and the University of Toronto, from multiple cross disciplines to study this important facet of human health.
It has long been understood that the vaginal microbiome is vital for women’s health and particularly important for reproductive success. However, until the advent of high throughput sequencing and genomic profiling of microbiomes, it was particularly challenging to study this area as there is relatively low diversity making changes in the profile subtle and the many organisms that are obligate anaerobes and are difficult to culture or unculturable. Adequate diagnostics have not been available to date and even research methods used to characterize this area were grossly inadequate.
Vaginal dysbiosis, wherein the vaginal ecosystem is disrupted is associated with higher rates of acquisition and transmission of sexually transmitted infections including HIV, and a highly symptomatic and disturbing condition called Bacterial vaginosis. In pregnant women, if vaginal dysbiosis occurs, this can result in subclinical infection of the placenta and membranes resulting in pathologic early rupture of the membranes (PPROM) or premature labour resulting in preterm delivery. Preterm birth is the highest cause of neonatal morbidity and mortality globally.
Our team has embarked on a series of studies utilizing 16srRNA and CPN60 gene targets to metagenomically profile and evaluate the microbiome associated with health both cross-sectionally and through the menstrual cycle as well as the vaginal microbiome in women with HIV infection as well as women with vulvovaginitis. We have also been assessing the microbiome in healthy pregnancies with successful term outcomes as well as women who have had the misfortune of preterm birth associated with PPROM and spontaneous preterm labour.
This talk will provide an overview of the profiling of the vaginal microbiome and selected results from our team will be presented to permit discussion of the value of the metagenomic study of the vaginal microbiome in personalizing and optimizing women’s in newborn’s health.
Dr. Deborah Money is a Professor at the University of British Columbia (UBC) in the Departments of Obstetrics and Gynecology, Medicine, and the School of Population and Public Health. She is a subspecialist in Reproductive Infectious Diseases. Dr. Money is the Vice President, Research at BC Women’s Hospital and Health Centre, Provincial Health Services Authority and Executive Director of the Women’s Health Research Institute (WHRI).
Dr. Money was trained with a BSc in Microbiology, and an MD at UBC followed by her residency in Obstetrics and Gynecology, also at UBC. She did a clinical and research Fellowship in Infectious Diseases at the University of Washington, and returned to UBC and to the Oak Street campus as the first individual in Canada with this combined training. She is the immediate past‐President (and first non‐US President) of the Infectious Diseases Society of Obstetrics and Gynecology (IDSOG), a 40 year old, US based academic society. In 2013 she was awarded the Society of Obstetrics and Gynecology (SOGC) Western Regional Award for achievement, the YWCA, metro Vancouver, Woman of Distinction Award and the Queen Elizabeth II Diamond Jubilee Medal.
Lecture Title: Treatment as Prevention – A Novel Strategy to Achieve Targeted Disease Elimination and Promote Healthcare Sustainability
HIV Treatment as Prevention to HIV
Building on the HIV Experience to Promote Healthcare Sustainability
Julio Montaner, OC, OBC, MD, DSc (Hon), FRCPC, FCCP, FACP, FRSC
Director, BC-Centre for Excellence in HIV/AIDS, St Paul’s Hospital, Providence Health Care
Professor and Head of Division of AIDS, University of British Columbia
UBC and St. Paul’s Hospital Foundation Chair in AIDS Research
UNAIDS Special Advisor, HIV Therapeutics
Following the discovery of combination antiretroviral therapy (cART) for HIV and AIDS, in part at St. Paul’s Hospital and the University of British Columbia, the provincial government agreed to expeditiously implement cART free of charge in BC. Within a matter of months, morbidity and mortality were decreasing significantly; furthermore, at the same time new HIV infections were unexpectedly declining, while syphilis rates were increasing province-wide. Based on additional ecological and cohort studies we concluded that cART was exerting a previously unrecognized secondary role preventing HIV transmission. We coined the term “Treatment as Prevention” (TasP) to characterize the ability of cART to decrease morbidity, mortality, and secondarily HIV transmission. In 2006, we proposed that cART could stop HIV disease progression and also reduce HIV transmission by over 90%, and that this could serve as a new strategy for the control of HIV/AIDS based on the expansion of the access to cART under the banner of TasP. Eventually, we showed TasP to be successful within NIDA funded pilot studies in British Columbia. Eventually this was confirmed in a randomized controlled trial, HPTN 052, published in 2011 that showed that cART was over 95% effective in preventing sexual transmission of HIV.
We have worked with the United Nations AIDS Programme (UNAIDS) to help disseminate the success of TasP globally. Specifically, in collaboration with UNAIDS, we developed a new global target for HIV treatment based on the success of our TasP strategy, referred to as the 90-90-90 Target. The new target proposes that by 2020, 90% of all people living with HIV should know their HIV status; 90% of them should be receiving sustained antiretroviral therapy; and 90% of them should have achieved sustained viral suppression. UNAIDS modelling suggests that achieving these targets by 2020 will decrease AIDS incidence, AIDS related deaths and new HIV infections by 90% from 2010 levels by 2030. The 90-90-90 Target was formally endorsed at the 2014 UN General Assembly (UNGASS) by the United Nations Secretary General, Mr. Ban Ki-Moon, who put forward the 90-90-90 Target as the UN cornerstone for the post-2015 Millennium Development Goals agenda. Since then, the 90-90-90 Target was formally embraced by the US, Panama, Spain, France, Argentina, Sierra Leone, South Africa, Brazil, India, China, Russia, among others. There is a growing sentiment that the 90-90-90 Target will be ratified as the new 2016 Sustainable Development Goal at the 2015 UNGASS.
More recently, it has become apparent that the strategy of Treatment as Prevention could be of value if applied to other contagious diseases, whether infectious or not. Our next immediate target is to export this strategy to the area of hepatitis C infection where this is particularly attractive given the emergence of the novel direct-acting agents, which makes treatment highly viable and extremely successful. We are currently finalizing details regarding the implementation of such a program, on a pilot basis, in the Downtown Eastside of Vancouver with the Ministry of Health. We are similarly exploring the use of this strategy to deal with conditions that are contagious -but not infectious- where the vector may be a form of “social contagion”. As such we are exploring the use of the strategy within the framework of Addiction Medicine.
Of note, Treatment as Prevention has proven cost-saving, because it’s effect on transmission acts as a multiplier in terms of return on the investment. This has led us to conceive a strategy of Treatment as Prevention driven targeted disease elimination to enhance healthcare sustainability.
Dr. Montaner is a Professor of Medicine and Head of the Division of AIDS at UBC. He also holds the endowed Chair in AIDS Research. He is the Director of the BC Centre for Excellence in HIV/AIDS and the Past-President of the International AIDS Society. He is the UNAIDS Global Advisor on HIV Therapeutics. He played a key role in establishing the efficacy of Highly Active Antiretroviral Therapy (HAART) and since then has established the role of ‘Treatment as Prevention’ using HAART to simultaneously decrease progression to AIDS and death, as well as HIV transmission.
Victoria M. Pratt, Ph.D., FACMG, Associate Professor, Director of Pharmacogenetics Laboratory, Indiana University School of Medicine
Lecture Title: Economics in Pharmacogenomics: An Implementation Reality Check
We will examine barriers and develop solutions for implementing pharmacogenomics in the Eskenazi Health System which serves as the primary health care safety-net in Indianapolis, IN. We will test the hypothesis that CLIA certified genotyping of 51 SNPs in 16 genes, targeted at 24 widely used drugs, is associated with significant reductions in hospital and outpatient economic costs and improved clinical outcomes.
Dr. Pratt is a Medical and Clinical Molecular Geneticist board-certified by the American College of Medical Genetics. She is currently Director of the Pharmacogenomics Laboratory at Indiana University School of Medicine. Prior to joining Indiana University, she was Chief Director, Molecular Genetics, for Quest Diagnostics Nichols Institute.
Dr. Pratt served on the U.S. Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society for the Oversight of Genetic Testing and the Advisory Committee on Hereditary Disorders in Newborns and Children. She also participated in the preparation of the Morbidity and Mortality Weekly Report for Best Practices in Molecular Genetic Testing for the Centers for Disease Control and Prevention (CDC). Dr. Pratt continues to serve on the CDC’s GeT-RM program for reference materials for Molecular Genetics. She is currently serving on the Institute of Medicine/National Academy of Medicine’s Roundtable on Translating Genomic-Based Research for Health and Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies.
Dr. Pratt is Past Chair of the Clinical Practice Committee and is currently a member of the Professional Relations committee, and is chair-elect of the Program committee for the Association of Molecular Pathology. She is a former advisor of EurogenTest for genetic test validation. Dr. Pratt serves on the American Medical Association’s (AMA’s) Molecular Pathology Current Procedural Terminology (CPT) Advisory committee.
Dr. Pratt has authored over 40 peer-reviewed manuscripts and book chapters. She is also an Associate Editor for the Journal of Molecular Pathology.
Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine, Indianapolis, IN in 1994. Her fellowship training was in Ph.D. Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.
Lecture Title: Development of pharmacogenomic predictors of severe adverse drug reactions to chemotherapy from pediatric cancer treatment
Development of pharmacogenomic predictors of severe adverse drug reactions to chemotherapy from pediatric cancer treatment”.
1Division of Translational Therapeutics, Departments of Pediatrics and Medical Genetics
University of British Columbia, Vancouver, BC, Canada (email: firstname.lastname@example.org)
The debilitating and lethal consequences of severe adverse drug reactions (ADRs) are a major problem of modern medicine. This problem is especially evident in the treatment of childhood cancer where there is a fine balance between cancer survival and the occurrence of severe life-threatening or permanently disabling ADRs. Despite improved rates of survival from childhood cancer (>80%), a staggering 73% of childhood cancer patients develop chronic health conditions and 42% develop disabling or life-threatening conditions as a consequence of their cancer treatment. It is increasingly evident that genomic differences can affect susceptibility to ADRs through variation in genes involved in drug metabolism and in pathways affected by, or responding to, drugs. My research aims to incorporate a patient’s genomic information to improve drug safety and effectiveness. The identification and characterization of these genomic factors is a complex process that requires a multidisciplinary collaborative team, beginning with in depth clinical characterization of patients, together with comprehensive genomic analyses, and ultimately requires a strategy to return these findings back to clinical practice for the benefit of patients in the future. My presentation will discuss exciting advances in understanding serious ADRs to several commonly used chemotherapy drugs and programs underway to implement these findings into clinical practice.
This work was supported by the Canadian Institute for Health Research (CIHR), Genome BC, the Drug Safety and Effectiveness Network (DSEN), the Canada Foundation for Innovation (CFI), the US National Institutes of Health (NIH), the Peter Wall Foundation, and the Hearing Foundation of Canada.
Dr. Colin Ross, MSc, PhD, is an Assistant Professor in the Departments of Pediatrics and Medical Genetics at the University of British Columbia at the Child and Family Research Institute (CFRI) at the BC Children’s Hospital in Vancouver. Dr. Ross’s research seeks to improve the safety and effectiveness of medications by incorporating genetic factors of drug response to better guide individual patient treatments. The debilitating and sometimes lethal consequences of severe adverse drug reactions (ADRs) are a striking problem in modern medicine. The high costs of ADRs to the health care system outweigh the costs of all medications combined. The consequences for patients who experience severe ADRs can be catastrophic. Dr. Ross helped establish the ‘Canadian Pharmacogenomics Network for Drug Safety’ (CPNDS), a network of clinicians and researchers in hospitals across Canada to identify patients that have suffered severe ADRs in order to develop genotype-based predictive tests. In the future, these ADRs could be prevented by identifying those patients at greatest risk before the drug is administered.
Josephine A. Sollano, Dr.PH
Lecture Title: Evidence Development to Support Reimbursement and Access of Personalized Medicines
As the development of oncologics and other specialty and biologics become increasingly targeted, pharmaceutical manufacturers must develop new approaches to demonstrating value of personalized therapies. Often times the standard approaches to the generation of cost-effectiveness and outcomes evidence fall short with respect to particular aspects of value that the new medicine delivers. In this discussion we will examine new approaches to the demonstration of value of personalized medicines that makes sense to a wide array of stakeholders; including patients, payors, and society.
Dr. Josephine Sollano is a Global Leader in Health Economics and Outcomes Research and Medical Communications Teams for Pfizer, Inc. within the Oncology Business Unit based in New York City. In her current role, Jo is responsible for the strategic development of economic and humanistic evidence required by payors, patients, and prescribers as well as the oversight for internal and external scientific communication across the oncology portfolio.
Prior to entering the pharmaceutical industry, Jo held several academic leadership roles including a senior policy and research position within InCHOIR at Columbia University, Executive Director of the Institute for Clinical Excellence at the NewYork-Presbyterian Medical Center, and Associate Vice President of Quality Management and Outcomes at the Northshore Long Island Jewish Healthcare System. Jo began her career in industry at Sanofi and later joined GlaxoSmithKline where she led a team responsible for Market Access and Health Economics & Outcomes in cardiovascular and metabolic diseases.
Jo holds a Doctoral degree in International Health Policy and Health Economics as well as a Master’s degree in Cardiovascular Epidemiology from Columbia University School of Public Health. Dr. Sollano has published papers, abstracts, and book chapters as well as lectured extensively on market access, health economics, and personalized medicine.
Title: Big Data and Data Analysis for Personalized Medicine
In a time of unprecedented scientific breakthroughs and technological advancements, personalized health care has the capacity to detect the onset of disease at its earliest stages, pre-empt the progression of disease, and, at the same time, increase the efficiency of the healthcare system by improving quality, accessibility, and affordability. Big Data technology in Personalized Medicine that leverages the notion of a “consumable, analytics-ready digital asset”, enables users to access large and diverse genomic datasets while protecting privacy, security and governance rules at the same time. From this, the development of major biological insights and medical advances can occur, including the development of more drugs with labels that include pharmacogenomics information.
As the President and CEO, Paul provides the vision and technical leadership at PHEMI. He also currently serves on the board of directors for Providence Health Care, advising on its subcommittees for innovation, quality, EMR and next-generation data strategies in healthcare. Paul also serves on the board of directors for Life Sciences BC and Molecular You, and is an advisor to the BC provincial government on next-generation data strategies. He is an adjunct professor in Big Data at Simon Fraser University and is a partner with Magellan Angel Partners. Paul lectures in technology, strategy and product management for the MBA program at SFU, and is a sought-after speaker on data innovation and strategy. He is a member of the Big Data Sub-Committee Working Group, the BC Institute for Health Innovation and serves on Genome BC’s Health Strategy Task Force. Paul is also an Ambassador for Privacy by Design.
Paul spent over a decade as the secretary/treasurer and technology adviser for the Michael Smith Foundation for Health Research, British Columbia’s health research support agency, and was one of the Entrepreneurs-in-Residence at SFU Venture Labs. Prior to his experience in healthcare and venture capital, Paul was the CTO and cofounder of OctigaBay Systems – a pioneer in high performance computing – which was acquired by Cray Inc, the world leader in supercomputing. He was also the cofounder and CTO of Abatis Systems, which was acquired by Redback Networks in one of the largest technology acquisitions in Canadian history. Paul’s early career included senior roles at Newbridge Networks and at technology companies in the UK. Paul was awarded Canada’s “Top 40 Under 40″ award in 2000. He holds an MBA from the Cranfield School of Management, a marketing diploma from the Chartered Institute of Marketing, a PhD in Electrical Engineering and an honours Bachelor’s degree from the University of Liverpool.